Research Briefs: Updates From EndoGastric Solutions, Cordis, Aptus Endosystems
This article was originally published in The Gray Sheet
RESPECT trial is designed to provide the kind of Level 1 evidence EndoGastic Solutions needs to persuade payers and physicians of the benefits of the EsophyX GERD-repair device. Cordis and Aptus Endosystems release new data at the Vascular Interventional Advances (VIVA) 2013 annual meeting in Las Vegas.
You may also be interested in...
With health care becoming increasingly data driven, third-party payors are requiring a higher level of evidence before making a positive coverage determination for a new technology or procedure. This has made the road to reimbursement much longer and tougher for device companies in general, and manufacturers of transoral devices for GERD are a prime example.
The endovascular abdominal aortic aneurysm repair (EVAR) market is one of the brightest growth opportunities in the medical device arena today. As a result, the competitive landscape is heating up as several new entrants stake their claim for a share of this $1+ billion opportunity.
Caution on robotic surgery from Ob/Gyn group. FDA gets closer to gaining access to most of fiscal 2013 user fees. More news.